New approaches to molecular cancer therapeutics

被引：300

作者：

Collins, Ian ^{[1
]}

Workman, Paul ^{[1
]}

机构：

[1] Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

来源：

NATURE CHEMICAL BIOLOGY | 2006年 / 2卷 / 12期

关键词：

D O I：

10.1038/nchembio840

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer drug development is leading the way in exploiting molecular biological and genetic information to develop 'personalized' medicine. The new paradigm is to develop agents that target the precise molecular pathology driving the progression of individual cancers. Drug developers have benefited from decades of academic cancer research and from investment in genomics, genetics and automation; their success is exemplified by high-profile drugs such as Herceptin ( trastuzumab), Gleevec ( imatinib), Tarceva (erlotinib) and Avastin (bevacizumab). However, only 5% of cancer drugs entering clinical trials reach marketing approval. Cancer remains a high unmet medical need, and many potential cancer targets remain undrugged. In this review we assess the status of the discovery and development of small-molecule cancer therapeutics. We show how chemical biology approaches offer techniques for interconnecting elements of the traditional linear progression from gene to drug, thereby providing a basis for increasing speed and success in cancer drug discovery.

引用

页码：689 / 700

页数：12

共 132 条

[1] Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].

Adams, J ;

Behnke, M ;

Chen, SW ;

Cruickshank, AA ;

Dick, LR ;

Grenier, L ;

Klunder, JM ;

Ma, YT ;

Plamondon, L ;

Stein, RL .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338

[2] Tools for kinetic modeling of biochemical networks [J].

Alves, Rui ;

Antunes, Fernando ;

Salvador, Armindo .

NATURE BIOTECHNOLOGY, 2006, 24 (06) :667-672

[3] The specificities of protein kinase inhibitors: an update [J].

Bain, J ;

McLauchlan, H ;

Elliott, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2003, 371 :199-204

[4] Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies [J].

Banerji, U ;

O'Donnell, A ;

Scurr, M ;

Pacey, S ;

Stapleton, S ;

Asad, Y ;

Simmons, L ;

Maloney, A ;

Raynaud, F ;

Campbell, M ;

Walton, M ;

Lakhani, S ;

Kaye, S ;

Workman, P ;

Judson, I .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4152-4161

[5] Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models [J].

Banerji, U ;

Walton, M ;

Raynaud, F ;

Grimshaw, R ;

Kelland, L ;

Valenti, M ;

Judson, I ;

Workman, P .

CLINICAL CANCER RESEARCH, 2005, 11 (19) :7023-7032

[6] The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation [J].

Barnett, SF ;

Bilodeau, MT ;

Lindsley, CW .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) :109-125

[7] Genetically engineered models have advantages over xenografts for preclinical studies [J].

Becher, OJ ;

Holland, EC .

CANCER RESEARCH, 2006, 66 (07) :3355-3358

[8] A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors [J].

Becker, F ;

Murthi, K ;

Smith, C ;

Come, J ;

Costa-Roldán, N ;

Kaufmann, C ;

Hanke, U ;

Degenhart, C ;

Baumann, S ;

Wallner, W ;

Huber, A ;

Dedier, S ;

Dill, S ;

Kinsman, D ;

Hediger, M ;

Bockovich, N ;

Meier-Ewert, S ;

Kluge, AF ;

Kley', N .

CHEMISTRY & BIOLOGY, 2004, 11 (02) :211-223

[9] Validating cancer drug targets [J].

Benson, John D. ;

Chen, Ying-Nan P. ;

Cornell-Kennon, Susan A. ;

Dorsch, Marion ;

Kim, Sunkyu ;

Leszczyniecka, Magdalena ;

Sellers, William R. ;

Lengauer, Christoph .

NATURE, 2006, 441 (7092) :451-456

[10] Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors [J].

Blencke, S ;

Ullrich, A ;

Daub, H .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (17) :15435-15440

← 1 2 3 4 5 6 7 8 9 10 →